<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141126">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765283</url>
  </required_header>
  <id_info>
    <org_study_id>HEP001</org_study_id>
    <nct_id>NCT01765283</nct_id>
  </id_info>
  <brief_title>Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)</brief_title>
  <official_title>A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promethera Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promethera Biosciences</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Italy: Istituto Superiore di Sanità</authority>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and to appraise the efficacy of one cycle
      of Hepastem (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC) infusions up
      to twelve months in paediatric patients suffering from CN or UCD.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse events and serious adverse events related to infusion and concomitant treatment</measure>
    <time_frame>up to 6 month post infusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessed by physical exam, vital signs , Clinical Lab tests and Morphology of liver, bile ducts and portal system by ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the technical intervention</measure>
    <time_frame>During 6 months for four time windows</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Reactogenicity of infusion,short and mid term safety of infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>long-term safety profile of HepaStem for both indications</measure>
    <time_frame>up to 12 months post infusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Physical examination, Vital signs,Clinical laboratory tests of liver enzymes, renal function, coagulation factors, hematology,Level of anti-HLA and other auto-immune markers, Adverse events and serious adverse events related to infusion and concomitant treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preliminary efficacy of HepaStem for both indications (CN and UCD) and for different weight cohorts</measure>
    <time_frame>0-6 months, 6-12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>characterize the engraftment capacity of HHLAPC for both indications</measure>
    <time_frame>baseline, and 6 month (optional at 12 month FU</time_frame>
    <safety_issue>No</safety_issue>
    <description>liver biopsy ,Enzymatic activity (quantitative) on the biopsies or, Donor sequences by RT PCR or in situ hybridisation (FISH) or immunohistochemistry.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Urea Cycle Disorders,</condition>
  <condition>Crigler Najjar Syndrome</condition>
  <arm_group>
    <arm_group_label>Hepastem Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5x106cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepastem Intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50x106cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepastem High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200x106cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HepaStem</intervention_name>
    <arm_group_label>Hepastem Low dose</arm_group_label>
    <arm_group_label>Hepastem Intermediate dose</arm_group_label>
    <arm_group_label>Hepastem High dose</arm_group_label>
    <other_name>HHALPC,Heterologous Human Adult Liver derived Progenitor Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is 18 years or older at time of screening.

          2. The subject presents acute liver failure.

          3. The subject presents clinical or radiological evidence of liver fibrosis or cirrhosis

          4. The subject presents or has a history of hepatic or extrahepatic malignancy

          5. The patient has a non-corrected cardiac malformation.

          6. The subject has a known medical or family history of coagulopathy.

          7. The subject participates currently in another clinical trial - except disease
             registry and observational HepaStem study.

          8. The subject underwent previous mature liver cell or stem cell transplantation or
             received an organ liver transplant.

          9. The subject has a contraindication to immunosuppressive therapy.

         10. The subject has a known hypersensitivity or allergy to the recommended antibiotics to
             prevent post-operative infections according to institutional guidelines, and
             basiliximab, solumedrol or tacrolimus unless alternative drugs can be used without
             risk for the patient.

         11. The subject has a known hypersensitivity or allergy to bivalirudin.

         12. The subject had or has a renal insufficiency treated by dialysis.

         13. The subject requires valproate therapy.

         14. The subject has a known hypersensitivity or allergy to contrast agents that cannot be
             treated adequately.

         15. The subject has a thrombosis of the portal vein or persisting impairment of
             anterograde portal blood flow.

         16. The subject has a porto systemic shunt or fistula assessed by Doppler US.

         17. For umbilical vein access: The subject has any contraindication for umbilical vein
             catheterization (eg omphalitis, peritonitis, necrotizing enterocolitis, etc)

         18. Any significant condition which in the Investigator's opinion may interfere with the
             subject's optimal participation in the study.

         19. Patients with disease of such severity that liver transplantation is an absolute
             indication.

         20. Patients with mild disease severity, easily controlled under standard of care therapy
             with no recurrent metabolic crises.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint Luc University Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis (UZ) Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis (UZ) Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre Cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre, CHRU Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone, CHU de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants, CHU de Toulouse</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center, Meyer Children's Hospital</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein-Kerem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of israel</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital London</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CN,</keyword>
  <keyword>UCD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crigler-Najjar Syndrome</mesh_term>
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
